계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Elpiscience Biopharmaceuticals
company
About
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies
- 101 - 250
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $105M
- Industries
- Biopharma,Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2017
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. Founded and managed by a team of biopharma industry leaders and scientists, Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
$260M
Elpiscience Biopharmaceuticals has raised a total of
$260M
in funding over 2 rounds. Their latest funding was raised on
May 13, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 13, 2021 | Series C | $105M | 2 | — | — | Detail |
| Dec 28, 2019 | Series B | $100M | 1 | — | — | Detail |
| Dec 3, 2018 | Series A | $35M | 1 | — | — | Detail |
| Apr 3, 2017 | Series A | $20M | 1 |
Lilly Asia Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Elpiscience Biopharmaceuticals is funded by 2 investors.
Superstring Capital
and Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
|
Lilly Asia Ventures
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
